DJS Antibodies, Ltd.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From DJS Antibodies, Ltd.
Bristol Myers Squibb believes LPA1 receptor inhibition is the best approach to meet the urgent need for well tolerated new pulmonary fibrosis treatment options that can improve symptoms and address the underlying cause of disease.
Excluding the multinational majors AstraZeneca and GSK, the UK has yet to produce a truly successful scaled pharma company, despite having boasted several innovative start-ups. Whether that represents a negative, however, is a matter for debate.
Deal Snapshot: AbbVie will acquire the privately-held UK antibody developer with preclinical assets.
- Drug Discovery Technologies
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.